LEMTRADA (Campath, alemtuzumab)

• LEMTRADA (Campath, alemtuzumab)

• Topics

• (Abst.) Siponimod following alemtuzumab for SPMS...

  Started by agate on 18 Aug, 2024 11:36

  Views: 256, Replies: 0

• Impact of previous DMT on effectiveness, safety outcomes in PwMS treated w/Lemtrada

  Started by agate on 05 Apr, 2021 15:17

  Views: 321, Replies: 0

• (Abst.) Alemtuzumab and rx medication use in the MS population

  Started by agate on 14 May, 2020 10:01

  Views: 317, Replies: 0

• (Abst.) Acute cardiotoxicity associated w/alemtuzumab infusion for MS

  Started by agate on 20 Apr, 2020 08:29

  Views: 343, Replies: 0

• (ACTRIMS) Fatal intercerebral hemorrhage secondary to alemtuzumab

  Started by agate on 14 Mar, 2020 15:06

  Views: 359, Replies: 0

• (Abst.) ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for MS

  Started by agate on 23 Feb, 2020 15:20

  Views: 353, Replies: 0

• Refractory chronic spontaneous urticaria after Lemtrada in MS

  Started by agate on 10 Jan, 2020 21:18

  Views: 231, Replies: 0

• (Abst.) Alemtuzumab-induced lung injury in 3 MS patients

  Started by agate on 03 Nov, 2019 19:27

  Views: 274, Replies: 0

• (MS Journal editorial) Emerging safety issues in alemtuzumab-treated MS patients

  Started by agate on 02 Aug, 2019 14:55

  Views: 280, Replies: 0

• EMA to restrict use of alemtuzumab pending review

  Started by agate on 14 May, 2019 16:34

  Views: 264, Replies: 0

• Alemtuzumab under scrutiny because of risk of stroke in some patients with MS

  Started by agate on 26 Apr, 2019 07:15

  Views: 375, Replies: 0

• (Abst.) Autoimmune nephropathies after Lemtrada treatment in PwMS

  Started by agate on 22 Apr, 2019 14:42

  Views: 270, Replies: 0

• (Abst.) Immune profiling of a patient w/alemtuzumab-associated PML

  Started by agate on 10 Apr, 2019 16:24

  Views: 291, Replies: 0

• (Abst.) Neutropenia w/fatal outcome in MS patient 23 days after alemtuzumab infusion

  Started by agate on 23 Jul, 2018 19:49

  Views: 367, Replies: 0

• More risks emerge for alemtuzumab in MS

  Started by agate on 08 Apr, 2018 16:27

  Views: 291, Replies: 0

• (Absts.) Two adverse events with Lemtrada reported

  Started by agate on 29 Jan, 2018 18:40

  Views: 413, Replies: 0

• (Abst.) Decreased platelet number in MS during alemtuzumab infusion...

  Started by agate on 25 Jan, 2018 16:31

  Views: 359, Replies: 0

• (Abst.) Activation of MS during Lemtrada therapy in 3 patients w/MS

  Started by agate on 21 Jan, 2018 15:41

  Views: 336, Replies: 0

• (Abst.) Alemtuzumab in MS: Lessons from social media in enhancing patient care

  Started by agate on 23 Dec, 2017 08:57

  Views: 393, Replies: 0

• Induction of new autoimmune diseases after alemtuzumab therapy for MS: Learning from adversity

  Started by agate on 12 Jun, 2017 20:40

  Views: 336, Replies: 0